17 Einträge gefunden

1. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3

   1. Reich, K
   2. Iversen, L
   3. Puig, L
   4. Lambert, J
   5. Mrowietz, U
   6. Kaplan Saday, K
   7. Warren, R B

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method

   1. Mrowietz, U
   2. Warren, R B
   3. Leonardi, C L
   4. Saure, D
   5. Petto, H
   6. Hartz, S
   7. Dossenbach, M

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis

   1. Reich, K
   2. Mrowietz, U
   3. Menter, A
   4. Griffiths, C E M
   5. Bagel, J
   6. Strober, B
   7. Nunez Gomez, N

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study

   1. Maul, J-T
   2. Augustin, M
   3. Sorbe, C
   4. Conrad, C
   5. Anzengruber, F
   6. Mrowietz, U
   7. Reich, K

   2021 - Forschungsinformationssystem des UKE
5. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study

   1. Reich, K
   2. Körber, A
   3. Mrowietz, U
   4. Sticherling, M
   5. Sieder, C
   6. Früh, J
   7. Bachhuber, T

   2021 - Forschungsinformationssystem des UKE
6. Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment

   1. Leutz, A
   2. Pinter, A
   3. Thaçi, D
   4. Augustin, M
   5. Schuster, C
   6. Fotiou, K
   7. Hundemer, H P

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
7. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study

   1. Reich, K
   2. Sullivan, J
   3. Arenberger, P
   4. Jazayeri, S
   5. Mrowietz, U
   6. Augustin, M
   7. Elewski, B

   2021 - Forschungsinformationssystem des UKE
8. A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)

   1. Pinter, A
   2. Hoffmann, M
   3. Reich, K
   4. Augustin, M
   5. Kaplan, K
   6. Gudjónsdóttir, S D
   7. Delvin, T

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
9. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment

   1. Reich, K
   2. Augustin, M
   3. Thaçi, D
   4. Pinter, A
   5. Leutz, A
   6. Henneges, C
   7. Schneider, E

   2020 - Forschungsinformationssystem des UKE
10. Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice

    1. Maul, J-T
    2. Navarini, A A
    3. Sommer, R
    4. Anzengruber, F
    5. Sorbe, C
    6. Mrowietz, U
    7. Drach, M

    2019 - Forschungsinformationssystem des UKE
11. Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients

    1. Augustin, M
    2. Sommer, R
    3. Kirsten, N
    4. Danckworth, A
    5. Radtke, M A
    6. Reich, K
    7. Thaci, D

    2019 - Forschungsinformationssystem des UKE
12. Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management

    1. Augustin, M
    2. Langenbruch, A
    3. Gutknecht, M
    4. Reich, K
    5. Körber, A
    6. Maaßen, D
    7. Mrowietz, U

    2018 - Forschungsinformationssystem des UKE
13. Einsatz von Systemtherapeutika und Biologika in der leitliniengerechten Therapie der mittelschweren bis schweren Psoriasis vulgaris

    1. Augustin, Matthias
    2. Enk, A
    3. von Kiedrowski, R
    4. Körber, Andreas
    5. Maaßen, D
    6. Mrowietz, U
    7. Peter, R U

    2017 - Forschungsinformationssystem des UKE
14. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic Treatments: results from the randomized controlled PRIME trial

    1. Sticherling, M
    2. Mrowietz, U
    3. Augustin, M
    4. Thaçi, D
    5. Melzer, N
    6. Hentschke, C
    7. Kneidl, J

    2017 - Forschungsinformationssystem des UKE
15. Mehr Sicherheit für unsere Patienten. Aktuelle Ergebnisse der Pharmakovigilanz in PsoBest

    1. Radtke, Marc Alexander
    2. Spehr, Christina
    3. Rustenbach, Stephan Jeff
    4. Mrowietz, U
    5. Thaci, D
    6. Reich, K
    7. Augustin, Matthias

    2017 - Forschungsinformationssystem des UKE
16. The German National Program on Psoriasis Health Care 2005-2015: Results and Experiences

    1. Augustin, M
    2. Eissing, L
    3. Langenbruch, A
    4. Enk, A
    5. Luger, T
    6. Maaßen, D
    7. Mrowietz, U

    2016 - Forschungsinformationssystem des UKE
17. Drug safety of systemic treatments for psoriasis: Results from The German Psoriasis Registry PsoBest

    1. Reich, K
    2. Mrowietz, U
    3. Radtke, M A
    4. Thaci, D
    5. Rustenbach, S J
    6. Spehr, C
    7. Augustin, M

    2015 - Forschungsinformationssystem des UKE